Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
A phase 3 trial of Dexamethasone, Pamidronate, Thalidomide and Zoledronic acid in Multiple myeloma, run by National Cancer Institute (NCI), completed.
Overview
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma is a phase 3 interventional study registered as NCT00033332 by National Cancer Institute (NCI), started 2002-04 and reaching its primary completion in 2006-03. Interventions recorded: dexamethasone, pamidronate disodium, thalidomide, zoledronic acid. Conditions recorded: Multiple Myeloma and Plasma Cell Neoplasm.
Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialCombination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
Shares Pamidronate, Thalidomide, Zoledronic acid, Multiple myeloma and the tag pipeline.
- TrialPamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Shares Pamidronate, Multiple myeloma and the tag pipeline.
- TrialComparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
Shares Zoledronic acid, Multiple myeloma and the tag pipeline.
- TrialAplidin - Dexamethasone in Relapsed/Refractory Myeloma
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
- TrialA Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
- TrialIbandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
Shares Zoledronic acid and the tag pipeline.
- TrialStudy of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
- TrialA Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
Shares Dexamethasone, Multiple myeloma and the tag pipeline.